Ertapenem sodium
Approved · EMAAlso known as Ertapenem, INVanz ADD-Vantage, Invanz.
Recent clinical, regulatory, research and industry developments relating to this drug.
PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network
Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known… Show full indicationShow less
Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1): Intra-abdominal infections Community acquired pneumonia Acute gynaecological infections Diabetic foot infections of the skin and soft tissue (see section 4.4) Prevention Ertapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Indication: Treatment Treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required:… Show full indicationShow less
Treatment Treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required: intra-abdominal infections; community-acquired pneumonia; acute gynaecological infections; diabetic foot infections of the skin and soft tissue. Prevention Invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network
Pharmacodynamics of Ertapenem in Patients With Urosepsis
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- International journal of antimicrobial agents1
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association1
- The Journal of antimicrobial chemotherapy1
- Alder J1
- Arvis P1
- Cha R1
- De Waele JJ1
- Desai NH1
- Gan WJ1
- Hampel B1
- Hsaiky LM1
- Affiliated Hospital of Jiangsu University1
- Beaumont Hospital - Dearborn1
- Eugene Applebaum College of Pharmacy and Health Sciences1
- Ghent University Hospital1
- Sichuan Academy of Medical Sciences1
- The 306th Hospital1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.